Immune checkpoint inhibitors (ICIs) plus chemotherapy have become the first-line standard therapy for non-oncogene addicted advanced non-small cell lung cancer (NSCLC) patients.
There is a lack of reliable biomarkers to predict treatment outcomes.
This study aimed to identify relevant lipids that can predict treatment outcomes in NSCLC patients receiving first-line ICIs plus chemotherapy via lipidomics.
